A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

NCT04185246 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiac Disease

Interventions

DRUG: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
DIAGNOSTIC_TEST: Echocardiogram

Sponsor

Trust Bio-sonics, Inc.

Collaborators

[object Object]